|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Novartis Quintiles |
| Information provided by: | Novartis |
| ClinicalTrials.gov Identifier: | NCT00050635 |
Purpose
Currently there is an ongoing clinical trial for patients with chemotherapy induced diarrhea. This trial is being conducted to evaluate the efficacy of two dose levels (30 mg and 40 mg) of an investigational drug in reducing the occurrence of severe (Grade 3 or 4) diarrhea during chemotherapy. Eligible patients must either have experienced NCI Common Toxicity Grade 1 – 4 chemotherapy-induced diarrhea during previous chemotherapy treatment or be experiencing Grade 1-4 chemotherapy-induced diarrhea currently.
In order to participate in this clinical trial, patients must be male or female 18 years of age or older. Inclusion into this investigational drug trial is based on the protocol entry criteria and a detailed evaluation from a participating trial investigator
| Condition | Intervention | Phase |
|
Neoplasms Diarrhea |
Drug: Sandostatin LAR Depot |
Phase IV |
| MedlinePlus related topics: | Cancer Diarrhea |
| Drug Information available for: | Octreotide Octreotide acetate |
| Study Type: | Interventional |
| Study Design: | Prevention, Randomized, Open Label, Uncontrolled, Parallel Assignment, Efficacy Study |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Key Inclusion criteria:
Key Exclusion criteria:
Contacts and Locations![]() |
Show 34 Study Locations |
| Novartis |
| Quintiles |
More Information
| Study ID Numbers: | CSMS995AUS38, STOP Trial |
| First Received: | December 17, 2002 |
| Last Updated: | May 24, 2006 |
| ClinicalTrials.gov Identifier: | NCT00050635 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|